Recent Quotes (30 days)
You have no recent quotes
| CAR | 34.61 | +3.7112.01% |  |
| PLCM | 12.25 | +1.3812.70% | |
| CC | 7.68 | +1.1217.07% | |
| CUDA | 18.43 | +2.9218.83% | |
| MITL | 7.21 | +1.1919.77% | |
| .IXIC | 4,956.76 | +79.951.64% | |
| .INX | 2,129.90 | +32.001.53% | |
| .DJI | 18,146.74 | +250.861.40% | |
| COMPOSITE | 4,971.58 | -45.07-0.90% | |
| ME | 45,744.29 | +349.920.77% | |
| IAR | 14,388.69 | -9.02-0.06% | |
| TASI | 6,499.88 | 0.000.00% | |
| WIG | 44,024.66 | -52.50-0.12% | |
| IB | 8,185.90 | +177.702.22% | |
| XU100 | 78,019.48 | -368.23-0.47% | |
| SET | 1,455.65 | -1.07-0.07% | |
| IBOV | 53,140.74 | +1,126.082.16% | |
| ATX | 2,074.11 | +30.831.51% | |
| SMI | 8,037.94 | +73.710.93% | |
| T25 | 1,412.44 | +14.341.03% | |
27.81
-13.01
(-31.87%)
Jul 8 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 27.50 - 32.19 |
| 52 week | 22.37 - 57.82 |
| Open | 32.01 |
| Vol / Avg. | 0.00/2.04M |
| Mkt cap | 2.00B |
| P/E | - |
| Div/yield | - |
| EPS | -2.65 |
| Shares | 105.54M |
| Beta | - |
| Inst. own | 72% |
Events
Aug 10, 2016
Q2 2016 Juno Therapeutics Inc Earnings Release (Estimated)
- 4:00PM EDT -
Jul 7, 2016
Juno Therapeutics Inc Reports Clinical Hold on the JCAR015 Phase II ROCKET Trial Call -
Jun 16, 2016
Juno Therapeutics Inc Annual Shareholders Meeting
Jun 10, 2016
Juno Therapeutics Inc Annual Shareholders Meeting (Estimated)
Jun 9, 2016
Juno Therapeutics Inc at Goldman Sachs Global Healthcare Conference -
Jun 7, 2016
Juno Therapeutics Inc at Jefferies Healthcare Conference -
May 10, 2016
Juno Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 9, 2016
Q1 2016 Juno Therapeutics Inc Earnings Call -
May 9, 2016
Q1 2016 Juno Therapeutics Inc Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '16) | 2015 | |
| Net profit margin | -727.75% | -1314.17% |
| Operating margin | -817.40% | -1340.10% |
| EBITD margin | - | -1273.86% |
| Return on average assets | -19.44% | -24.75% |
| Return on average equity | -24.25% | -31.29% |
| Employees | 373 | - |
| CDP Score | - | - |
Address
307 Westlake Ave N Ste 300
SEATTLE, WA 98109-5235
United States - Map
+1-206-5821600 (Phone)
+1-302-6365454 (Fax)
SEATTLE, WA 98109-5235
United States - Map
+1-206-5821600 (Phone)
+1-302-6365454 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Prices are not from all markets.
Sources include SIX.
Prices are not from all markets.
Sources include SIX.
Advertisement
Description
Juno Therapeutics, Inc. is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16/IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial for treatment of various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of adult myeloid leukemia, myelodysplasic syndrome and chronic myeloid leukemia.
Officers and directors
| Howard H. Pien | Independent Chairman of the Board | |
| Hans Edgar Bishop | President, Chief Executive Officer, Director | |
| Steven D. Harr M.D. | Chief Financial Officer, Head of Corporate Development | |
| Hyam I. Levitsky M.D | Executive vice president - Research, chief scientific officer | |
| Robert Azelby | Executive Vice President, Chief Commercial Officer | |
| Bernard J. Cassidy | General Counsel, Secretary | |
| Hal V. Barron M.D. | Independent Director | |
| Thomas O. Daniel M.D. | Director | |
| Richard Klausner M.D. | Director | |
| Marc Tessier-Lavigne Ph.D. | Independent Director |